Trade AstraZeneca ^AZN

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

In the clinic for April 6, 2026 | BioWorld

AstraZeneca's Imfinzi Combines with Lenvatinib to Transform Liver Cancer Treatment, ETPharma

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Manufacturing Stocks Worth Watching - April 5th - Daily Political

Aberdeen Group plc Grows Stake in Astrazeneca Plc $AZN

AstraZeneca (AZN) Receives a Buy from Goldman Sachs | Markets Insider

AstraZeneca (LON:AZN) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp

AstraZeneca: Imfinzi, Imjudo Combo With Lenvatinib And TACE Show Positive Phase III Trial Results

Deutsche Bank Maintains Sell on AstraZeneca (AZN)

AstraZeneca Rare Disease Data Puts Efzimfotase Alfa In Investor Focus

AstraZeneca's Efzimfotase Data Test Rare Disease Growth Story

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results

PFG Private Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN - Markets Daily

Moody Lynn & Lieberson LLC Increases Holdings in Astrazeneca Plc $AZN

Promising Manufacturing Stocks To Watch Now - March 29th - Markets Daily

PFG Private Wealth Management LLC Invests $297,000 in Astrazeneca Plc $AZN - Stock Observer

AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations

Sun Pharmaceuticals Industries Ltd Futures Share Price & Chart Today | IIFL Capital

Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer

GCC Growth Summit 2026: Can Indian GCCs Effectively Navigate the Challenge of Saying No?, ETGCC

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results - Update | Morningstar

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Boston Common Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN

Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC

AstraZeneca: Efzimfotase Alfa Shows Positive Results From Phase III Programme

AstraZeneca Drug Candidate Achieves Mixed Results in Trials for Rare Disease | Morningstar

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC

Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Promising Manufacturing Stocks To Watch Today - March 30th

Telnyx package latest hit in PyPI supply-chain compromise • The Register

Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients

Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

MOR Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN

MOR Wealth Management LLC Takes $526,000 Position in Astrazeneca Plc $AZN - Markets Daily

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million

Dakota Wealth Management Purchases 5,595 Shares of Astrazeneca Plc $AZN

UK Value Stock Picks Including Serica Energy For Estimated Discount Opportunities

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

A renaissance in targeting the PI3K/AKT/mTOR pathway

Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

USA Financial Formulas Acquires Shares of 10,063 Astrazeneca Plc $AZN

LVW Advisors LLC Decreases Holdings in Astrazeneca Plc $AZN - Markets Daily

LVW Advisors LLC Sells 3,172 Shares of Astrazeneca Plc $AZN - Stock Observer

USA Financial Formulas Takes Position in Astrazeneca Plc $AZN - Daily Political

Manufacturing Stocks To Add to Your Watchlist - March 28th - Markets Daily

Sax Wealth Advisors LLC Makes New $404,000 Investment in Astrazeneca Plc $AZN - Markets Daily

Nordea Investment Management AB Grows Holdings in Astrazeneca Plc $AZN

AstraZeneca COPD Breakthrough Puts Tozorakimab And Valuation In Sharper Focus

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback

AstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average - Here's What Happened - Markets Daily

AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

UK's FTSE 100 Ends Week Little Changed; AstraZeneca Shares Gain

Morning News Wrap-Up: 3/27/26: Today's Biggest Stock Market Stories | Markets Insider

Astrazeneca (NYSE:AZN) Shares Gap Up - Here's What Happened

AstraZeneca Shares Rise After Lung Drug Hits Goals in Late-Stage Trials - Update | Morningstar

AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study

Stocks to Watch: Unity, Carnival, AstraZeneca - Yahoo Actualités France

Live Nasdaq Composite: Markets Tank as Oil Soars on Mideast Fatigue

AstraZeneca Zips Higher On Its Double Win In COPD Treatment - Yahoo News Canada

AstraZeneca stock jumps 4% after surprise lung disease trial win

AstraZeneca's Tozorakimab Shows Promise in Reducing COPD Flare-Ups, ETPharma

Stocks making the biggest moves premarket: AZN, U, COIN

China approves innovative breast cancer therapy by Daiichi Sankyo, AstraZeneca - Chinadaily.com.cn

AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials

AstraZeneca's Tozorakimab Meets Primary Endpoint In Phase III COPD Trials

Markedsoppdatering om samarbeidet med AstraZeneca

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...

Apple's Expanding Enterprise Footprint to Boost Sales: What's Ahead?

Innate Pharma Q4 Earnings Call Highlights - Daily Political

Astrazeneca Plc (NYSE:AZN) Receives Average Rating of "Moderate Buy" from Analysts

AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average - What's Next?

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous

INNATE PHARMA PRÉSENTE SES RÉSULTATS FINANCIERS ET L'AVANCÉE DE SON PORTEFEUILLE POUR L'ANNÉE 2025

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

4568: Oncology Pipeline Progress Will Drive Further Upside For Shares

AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers

2 FTSE 100 blue-chips to consider for a new £20k Stocks and Shares ISA

Hengrui Medicine's Innovative Drug Revenue Accounts for Nearly Sixty Percent, BD Restructuring Internationalization Anchor Value

Professional Advisory Services Inc. Has $28.12 Million Stock Holdings in Astrazeneca Plc $AZN

12 Best UK Stocks to Buy According to Hedge Funds

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

£20,000 invested in a Stocks and Shares ISA 5 years ago could now be worth…

Procyon Advisors LLC Has $727,000 Stake in Astrazeneca Plc $AZN - Daily Political

Astrazeneca Plc $AZN Shares Sold by Montecito Bank & Trust - Daily Political

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

TEM stock price analysis: Why Tempus AI Stock Up Today?

FTSE 100 index near one-month lows as global sentiment sours

Moderna share price jumps as Oppenheimer upgrades stock

Week ahead: RBA poised to hike?

FTSE 100 Index: London stocks start week sharply lower

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk